10,31 $
0,29 %
Nasdaq, 3. Oktober, 22:10 Uhr
ISIN
US82835W1080
Symbol
SPRY
Berichte

Silverback Therapeutics Aktie News

Neutral
GlobeNewsWire
7 Tage alt
Initial $100 million term loan to propel market share growth in the U.S. SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced it has entered into a senior s...
Positiv
Seeking Alpha
13 Tage alt
ARS Pharmaceuticals offers significant upside driven by neffy, the only FDA-approved needle-free epinephrine nasal spray for severe allergic reactions. ARS faces near-term pressure from a patent challenge by Lupin, but even pessimistic scenarios suggest the stock is at least fairly valued. Base case fair value is $24.29 (138% upside), while the pessimistic scenario yields $12.25 (20% upside) fr...
Neutral
GlobeNewsWire
19 Tage alt
– Accomplished biopharma executive and entrepreneur brings a 25-year track record of upscaling valuable companies and realizing the potential of their innovations – SAN DIEGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, today announced the appointment of Laura Shawver, Ph.D.
Neutral
GlobeNewsWire
28 Tage alt
Findings accepted for publication in the official journal of the American College of Allergy, Asthma and Immunology About 9 out of every 10 patients experiencing anaphylaxis were effectively treated with a single dose of neffy Results suggest real-world effectiveness of neffy is consistent with that historically reported for epinephrine injection SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- AR...
Neutral
GlobeNewsWire
etwa ein Monat alt
SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced that Richard Lowenthal, Co-Founder, President and CEO and Eric Karas, Chief Commercial Officer will participate in pres...
Neutral
Seeking Alpha
etwa 2 Monate alt
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY ) Q2 2025 Earnings Conference Call August 13, 2025 8:30 AM ET Company Participants Eric Karas - Chief Commercial Officer Justin Chakma - Chief Business Officer Kathleen D. Scott - Chief Financial Officer Richard E.
Neutral
GlobeNewsWire
etwa 2 Monate alt
$15.7 million in revenue, including $12.8 million in neffy U.S. net product revenue in second quarter of 2025
Neutral
GlobeNewsWire
2 Monate alt
SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Wednesday, August 13, 2025, at 5:30 a.m. PT / 8:30 a.m.

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen